Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Hypertension Reports
Published in: Current Hypertension Reports 11/2016

Open Access 01-11-2016 | Antihypertensive Agents: Mechanisms of Drug Action (ME Ernst, Section Editor)

Effects of Aspirin on Endothelial Function and Hypertension

Authors: Mikhail S. Dzeshka, Alena Shantsila, Gregory Y. H. Lip

Published in: Current Hypertension Reports | Issue 11/2016

Login to get access

Abstract

Purpose of review

Endothelial dysfunction is intimately related to the development of various cardiovascular diseases, including hypertension, and is often used as a target for pharmacological treatment. The scope of this review is to assess effects of aspirin on endothelial function and their clinical implication in arterial hypertension.

Recent findings

Emerging data indicate the role of platelets in the development of vascular inflammation due to the release of proinflammatory mediators, for example, triggered largely by thromboxane. Vascular inflammation further promotes oxidative stress, diminished synthesis of vasodilators, proaggregatory and procoagulant state. These changes translate into vasoconstriction, impaired circulation and thrombotic complications. Aspirin inhibits thromboxane synthesis, abolishes platelets activation and acetylates enzymes switching them to the synthesis of anti-inflammatory substances.

Summary

Aspirin pleiotropic effects have not been fully elucidated yet. In secondary prevention studies, the decrease in cardiovascular events with aspirin outweighs bleeding risks, but this is not the case in primary prevention settings. Ongoing trials will provide more evidence on whether to expand the use of aspirin or stay within current recommendations.
Literature
1.
Cahill PA, Redmond EM. Vascular endothelium—gatekeeper of vessel health. Atherosclerosis. 2016;248:97–109.CrossRefPubMed
2.
Deshko MS, Snezhitsky VA, Dolgoshey TS, Madekina GA, Stempen TP. Flow-mediated dilation in patients with paroxysmal atrial fibrillation: initial evaluation, treatment results, pathophysiological correlates. Europace : Eur, Arrhythmias, Cardiac Electrophysiol: J Working Groups Cardiac Pacing, Arrhythmias, Cardiac Cell Electrophysiol Eur Soc Cardiol. 2011;13(suppl 3).
3.
Kornej J, Apostolakis S, Bollmann A, Lip GY. The emerging role of biomarkers in atrial fibrillation. Can J Cardiol. 2013;29(10):1181–93.CrossRefPubMed
4.
Lehoux S, Jones EA. Shear stress, arterial identity and atherosclerosis. Thromb Haemost. 2016;115(3):467–73.CrossRefPubMed
5.
6.
De Miguel C, Rudemiller NP, Abais JM, Mattson DL. Inflammation and hypertension: new understandings and potential therapeutic targets. Curr Hypertens Rep. 2014;17(1):1–10.
7.
Schrottmaier WC, Kral JB, Badrnya S, Assinger A. Aspirin and P2Y12 inhibitors in platelet-mediated activation of neutrophils and monocytes. Thromb Haemost. 2015;114(9):478–89.CrossRefPubMed
8.
Muller KA, Chatterjee M, Rath D, Geisler T. Platelets, inflammation and anti-inflammatory effects of antiplatelet drugs in ACS and CAD. Thromb Haemost. 2015;114(3):498–518.CrossRefPubMed
9.
• Thomas MR, Storey RF. The role of platelets in inflammation. Thromb Haemost. 2015;114(9):449–58. Comprehensive review of the role of platelets in inflammation.CrossRefPubMed
10.
Hohlfeld T, Schrör K. Antiinflammatory effects of aspirin in ACS: relevant to its cardiocoronary actions? Thromb Haemost. 2015;114(9):469–77.CrossRefPubMed
11.
12.
13.
• Dai SX, Li WX, Li GH, Huang JF. Proteome-wide prediction of targets for aspirin: new insight into the molecular mechanism of aspirin. Peer J. 2016;4:e1791. An analysis showing multiple targets for aspirin.CrossRefPubMedPubMedCentral
14.
Serebruany VL, Cherepanov V, Cabrera-Fuentes HA, Kim MH. Solid cancers after antiplatelet therapy: confirmations, controversies, and challenges. Thromb Haemost. 2015;114(12):1104–12.CrossRefPubMed
15.
Nagelschmitz J, Blunck M, Kraetzschmar J, Ludwig M, Wensing G, Hohlfeld T. Pharmacokinetics and pharmacodynamics of acetylsalicylic acid after intravenous and oral administration to healthy volunteers. Clin Pharmacol: Adv Appl. 2014;6:51–9.
16.
17.
Petrucci G, Rizzi A, Cavalca V, Habib A, Pitocco D, Veglia F, et al. Patient-independent variables affecting the assessment of aspirin responsiveness by serum thromboxane measurement. Thrombosis Haemostasis. 2016(2016-07-21 00:00:00).
18.
Gleim S, Stitham J, Tang WH, Li H, Douville K, Chelikani P, et al. Human thromboxane A2 receptor genetic variants: in silico, in vitro and "in platelet" analysis. PLoS ONE. 2013;8(6), e67314.CrossRefPubMedPubMedCentral
19.
Katugampola SD, Davenport AP. Thromboxane receptor density is increased in human cardiovascular disease with evidence for inhibition at therapeutic concentrations by the AT(1) receptor antagonist losartan. Br J Pharmacol. 2001;134(7):1385–92.CrossRefPubMedPubMedCentral
20.
21.
Koenen RR. The prowess of platelets in immunity and inflammation. Thrombosis Haemostasis. 2016(2016-07-07 00:00:00).
22.
Soon ASC, Chua JW, Becker DL. Connexins in endothelial barrier function – novel therapeutic targets countering vascular hyperpermeability. Thrombosis Haemostasis. 2016(2016-08-04 00:00:00).
23.
Pierini D, Bryan NS. Nitric oxide availability as a marker of oxidative stress. Methods Mol Biol (Clifton, NJ). 2015;1208:63–71.CrossRef
24.
Higashi Y, Maruhashi T, Noma K, Kihara Y. Oxidative stress and endothelial dysfunction: clinical evidence and therapeutic implications. Trends Cardiovasc Med. 2014;24(4):165–9.CrossRefPubMed
25.
Ball SK, Field MC, Tippins JR. Regulation of thromboxane receptor signaling at multiple levels by oxidative stress-induced stabilization, relocation and enhanced responsiveness. PLoS ONE. 2010;5(9), e12798.CrossRefPubMedPubMedCentral
26.
Muzaffar S, Shukla N, Massey Y, Angelini GD, Jeremy JY. NADPH oxidase 1 mediates upregulation of thromboxane A2 synthase in human vascular smooth muscle cells: inhibition with iloprost. Eur J Pharmacol. 2011;658(2–3):187–92.CrossRefPubMed
27.
Zhang M, Song P, Xu J, Zou MH. Activation of NAD(P)H oxidases by thromboxane A2 receptor uncouples endothelial nitric oxide synthase. Arterioscler Thromb Vasc Biol. 2011;31(1):125–32.CrossRefPubMed
28.
Francois H, Athirakul K, Mao L, Rockman H, Coffman TM. Role for thromboxane receptors in angiotensin-II-induced hypertension. Hypertension. 2004;43(2):364–9.CrossRefPubMed
29.
Sparks MA, Makhanova NA, Griffiths RC, Snouwaert JN, Koller BH, Coffman TM. Thromboxane receptors in smooth muscle promote hypertension, vascular remodeling, and sudden death. Hypertension. 2013;61(1):166–73.CrossRefPubMed
30.
Schildknecht S, van der Loo B, Weber K, Tiefenthaler K, Daiber A, Bachschmid MM. Endogenous peroxynitrite modulates PGHS-1-dependent thromboxane A2 formation and aggregation in human platelets. Free Radic Biol Med. 2008;45(4):512–20.CrossRefPubMed
31.
Zou MH. Peroxynitrite and protein tyrosine nitration of prostacyclin synthase. Prostaglandins Lipid Mediators. 2007;82(1–4):119–27.CrossRef
32.
Nevitt C, McKenzie G, Christian K, Austin J, Hencke S, Hoying J, et al. Physiological levels of thrombospondin-1 decrease NO-dependent vasodilation in coronary microvessels from aged rats. Am J Physiol Heart Circ Physiol. 2016;310(11):H1842–H50.CrossRefPubMed
33.
Muzaffar S, Jeremy JY, Angelini GD, Shukla N. NADPH oxidase 4 mediates upregulation of type 4 phosphodiesterases in human endothelial cells. J Cell Physiol. 2012;227(5):1941–50.CrossRefPubMed
34.
Lassegue B, San Martin A, Griendling KK. Biochemistry, physiology, and pathophysiology of NADPH oxidases in the cardiovascular system. Circ Res. 2012;110(10):1364–90.CrossRefPubMedPubMedCentral
35.
Gamez-Mendez AM, Vargas-Robles H, Rios A, Escalante B. Oxidative stress-dependent coronary endothelial dysfunction in obese mice. PLoS ONE. 2015;10(9), e0138609.CrossRefPubMedPubMedCentral
36.
Liu CQ, Leung FP, Wong SL, Wong WT, Lau CW, Lu L, et al. Thromboxane prostanoid receptor activation impairs endothelial nitric oxide-dependent vasorelaxations: the role of Rho kinase. Biochem Pharmacol. 2009;78(4):374–81.CrossRefPubMed
37.
Banerjee D, Mazumder S, Sinha AK. The role of inhibition of nitric oxide synthesis in the aggregation of platelets due to the stimulated production of thromboxane A2. Blood Coagul Fibrinolysis: Int J Haemostasis Thrombosis. 2014;25(6):585–91.
38.
Banerjee D, Mazumder S, Kumar Sinha A. Involvement of nitric oxide on calcium mobilization and arachidonic acid pathway activation during platelet aggregation with different aggregating agonists. Int J Biomed Sci: IJBS. 2016;12(1):25–35.PubMedPubMedCentral
39.
Ellinsworth DC, Shukla N, Fleming I, Jeremy JY. Interactions between thromboxane A(2), thromboxane/prostaglandin (TP) receptors, and endothelium-derived hyperpolarization. Cardiovasc Res. 2014;102(1):9–16.CrossRefPubMed
40.
Vanhoutte PM. Endothelium-dependent contractions in hypertension: when prostacyclin becomes ugly. Hypertension. 2011;57(3):526–31.CrossRefPubMed
41.
Luo W, Liu B, Zhou Y. The endothelial cyclooxygenase pathway: insights from mouse arteries. Eur J Pharmacol. 2016;780:148–58.CrossRefPubMed
42.
Kirkby NS, Lundberg MH, Harrington LS, Leadbeater PD, Milne GL, Potter CM, et al. Cyclooxygenase-1, not cyclooxygenase-2, is responsible for physiological production of prostacyclin in the cardiovascular system. Proc Natl Acad Sci U S A. 2012;109(43):17597–602.CrossRefPubMedPubMedCentral
43.
Zhou Y, Luo W, Zhang Y, Li H, Huang D, Liu B. Cyclo-oxygenase-1 or −2-mediated metabolism of arachidonic acid in endothelium-dependent contraction of mouse arteries. Exp Physiol. 2013;98(7):1225–34.CrossRefPubMed
44.
Patrono C. Cardiovascular effects of nonsteroidal anti-inflammatory drugs. Curr Cardiol Rep. 2016;18(3):1–8.CrossRef
45.
Tang SY, Monslow J, Todd L, Lawson J, Pure E, FitzGerald GA. Cyclooxygenase-2 in endothelial and vascular smooth muscle cells restrains atherogenesis in hyperlipidemic mice. Circulation. 2014;129(17):1761–9.CrossRefPubMedPubMedCentral
46.
Kirkby NS, Zaiss AK, Urquhart P, Jiao J, Austin PJ, Al-Yamani M, et al. LC-MS/MS confirms that COX-1 drives vascular prostacyclin whilst gene expression pattern reveals non-vascular sites of COX-2 expression. PLoS ONE. 2013;8(7), e69524.CrossRefPubMedPubMedCentral
47.
Liu B, Li Z, Zhang Y, Luo W, Zhang J, Li H, et al. Vasomotor reaction to cyclooxygenase-1-mediated prostacyclin synthesis in carotid arteries from two-kidney-one-clip hypertensive mice. PLoS ONE. 2015;10(8), e0136738.CrossRefPubMedPubMedCentral
48.
Li S, Liu B, Luo W, Zhang Y, Li H, Huang D, et al. Role of cyclooxygenase-1 and −2 in endothelium-dependent contraction of atherosclerotic mouse abdominal aortas. Clin Exp Pharmacol Physiol. 2016;43(1):67–74.CrossRefPubMed
49.
Tang EH, Vanhoutte PM. Gene expression changes of prostanoid synthases in endothelial cells and prostanoid receptors in vascular smooth muscle cells caused by aging and hypertension. Physiol Genomics. 2008;32(3):409–18.CrossRefPubMed
50.
Pratico D, Tillmann C, Zhang ZB, Li H, FitzGerald GA. Acceleration of atherogenesis by COX-1-dependent prostanoid formation in low density lipoprotein receptor knockout mice. Proc Natl Acad Sci U S A. 2001;98(6):3358–63.CrossRefPubMedPubMedCentral
51.
Feletou M, Verbeuren TJ, Vanhoutte PM. Endothelium-dependent contractions in SHR: a tale of prostanoid TP and IP receptors. Br J Pharmacol. 2009;156(4):563–74.CrossRefPubMedPubMedCentral
52.
Liu B, Luo W, Zhang Y, Li H, Zhu N, Huang D, et al. Involvement of cyclo-oxygenase-1-mediated prostacyclin synthesis in the vasoconstrictor activity evoked by ACh in mouse arteries. Exp Physiol. 2012;97(2):277–89.CrossRefPubMed
53.
Liu D, Liu B, Luo W, Li H, Zhang Y, Zhou Y. A vasoconstrictor response to COX-1-mediated prostacyclin synthesis in young rat renal arteries that increases in prehypertensive conditions. Am J Physiol Heart Circ Physiol. 2015;309(5):H804–11.PubMed
54.
White SJ, Newby AC, Johnson TW. Endothelial erosion of plaques as a substrate for coronary thrombosis. Thromb Haemost. 2016;115(3):509–19.CrossRefPubMed
55.
Piepoli MF, Hoes AW, Agewall S, Albus C, Brotons C, Catapano AL, et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2016.
56.
Romero M, Leon-Gomez E, Lobysheva I, Rath G, Dogne JM, Feron O, et al. Effects of BM-573 on endothelial dependent relaxation and increased blood pressure at early stages of atherosclerosis. PLoS ONE. 2016;11(3), e0152579.CrossRefPubMedPubMedCentral
57.
Huang SW, Kuo HL, Hsu MT, Tseng YJ, Lin SW, Kuo SC, et al. A novel thromboxane receptor antagonist, nstpbp5185, inhibits platelet aggregation and thrombus formation in animal models. Thrombosis Haemostasis. 2016;116(2).
58.
Francois H, Makhanova N, Ruiz P, Ellison J, Mao L, Rockman HA, et al. A role for the thromboxane receptor in L-NAME hypertension. Am J Physiol Renal Physiol. 2008;295(4):F1096–102.CrossRefPubMedPubMedCentral
59.
Cayatte AJ, Du Y, Oliver-Krasinski J, Lavielle G, Verbeuren TJ, Cohen RA. The thromboxane receptor antagonist S18886 but not aspirin inhibits atherogenesis in apo E-deficient mice: evidence that eicosanoids other than thromboxane contribute to atherosclerosis. Arterioscler Thromb Vasc Biol. 2000;20(7):1724–8.CrossRefPubMed
60.
Del Turco S, Basta G, Lazzerini G, Chancharme L, Lerond L, De Caterina R. Involvement of the TP receptor in TNF-alpha-induced endothelial tissue factor expression. Vasc Pharmacol. 2014;62(2):49–56.CrossRef
61.
Sebekova K, Ramuscak A, Boor P, Heidland A, Amann K. The selective TP receptor antagonist, S18886 (terutroban), attenuates renal damage in the double transgenic rat model of hypertension. Am J Nephrol. 2008;28(1):47–53.CrossRefPubMed
62.
Gelosa P, Sevin G, Pignieri A, Budelli S, Castiglioni L, Blanc-Guillemaud V, et al. Terutroban, a thromboxane/prostaglandin endoperoxide receptor antagonist, prevents hypertensive vascular hypertrophy and fibrosis. Am J Physiol Heart Circ Physiol. 2011;300(3):H762–8.CrossRefPubMed
63.
Gelosa P, Ballerio R, Banfi C, Nobili E, Gianella A, Pignieri A, et al. Terutroban, a thromboxane/prostaglandin endoperoxide receptor antagonist, increases survival in stroke-prone rats by preventing systemic inflammation and endothelial dysfunction: comparison with aspirin and rosuvastatin. J Pharmacol Exp Ther. 2010;334(1):199–205.CrossRefPubMed
64.
Bousser MG, Amarenco P, Chamorro A, Fisher M, Ford I, Fox KM, et al. Terutroban versus aspirin in patients with cerebral ischaemic events (PERFORM): a randomised, double-blind, parallel-group trial. Lancet (London, England). 2011;377(9782):2013–22.CrossRef
65.
Bots ML, Ford I, Lloyd SM, Laurent S, Touboul PJ, Hennerici MG. Thromboxane prostaglandin receptor antagonist and carotid atherosclerosis progression in patients with cerebrovascular disease of ischemic origin: a randomized controlled trial. Stroke; J Cerebral Circ. 2014;45(8):2348–53.CrossRef
66.
Chan MV, Knowles RBM, Lundberg MH, Tucker AT, Mohamed NA, Kirkby NS, et al. P2Y12 receptor blockade synergizes strongly with nitric oxide and prostacyclin to inhibit platelet activation. Br J Clin Pharmacol. 2016;81(4):621–33.CrossRefPubMedPubMedCentral
67.
Thomas MR, Storey RF. Effect of P2Y12 inhibitors on inflammation and immunity. Thromb Haemost. 2015;114(9):490–7.CrossRefPubMed
68.
Frey AJ, Ibrahim S, Gleim S, Hwa J, Smyth EM. Biased suppression of TP homodimerization and signaling through disruption of a TM GxxxGxxxL helical interaction motif. J Lipid Res. 2013;54(6):1678–90.CrossRefPubMedPubMedCentral
69.
70.
Jung SB, Kim CS, Naqvi A, Yamamori T, Mattagajasingh I, Hoffman TA, et al. Histone deacetylase 3 antagonizes aspirin-stimulated endothelial nitric oxide production by reversing aspirin-induced lysine acetylation of endothelial nitric oxide synthase. Circ Res. 2010;107(7):877–87.CrossRefPubMedPubMedCentral
71.
Kabirian F, Amoabediny G, Haghighipour N, Salehi-Nik N, Zandieh-Doulabi B. Nitric oxide secretion by endothelial cells in response to fluid shear stress, aspirin, and temperature. J Biomed Mater Res A. 2015;103(3):1231–7.CrossRefPubMed
72.
Ghosh R, Bank S, Maji UK, Bhattacharya R, Guha S, Khan NN, et al. The effect of acetyl salicylic acid induced nitric oxide synthesis in the normalization of hypertension through the stimulation of renal cortexin synthesis and by the inhibition of dermcidin isoform 2, a hypertensive protein production. Int J Biomed Sci: IJBS. 2014;10(3):158–66.PubMedPubMedCentral
73.
Karmohapatra SK, Chakraborty K, Kahn NN, Sinha AK. The role of nitric oxide in aspirin induced thrombolysis in vitro and the purification of aspirin activated nitric oxide synthase from human blood platelets. Am J Hematol. 2007;82(11):986–95.CrossRefPubMed
74.
Hennekens CH, Schneider WR, Pokov A, Hetzel S, Demets D, Serebruany V, et al. A randomized trial of aspirin at clinically relevant doses and nitric oxide formation in humans. J Cardiovasc Pharmacol Ther. 2010;15(4):344–8.CrossRefPubMedPubMedCentral
75.
Hetzel S, DeMets D, Schneider R, Borzak S, Schneider W, Serebruany V, et al. Aspirin increases nitric oxide formation in chronic stable coronary disease. J Cardiovasc Pharmacol Ther. 2013;18(3):217–21.CrossRefPubMedPubMedCentral
76.
Schror K, Rauch BH. Aspirin and lipid mediators in the cardiovascular system. Prostaglandins Lipid Mediators. 2015;121(Pt A):17–23.CrossRef
77.
Romano M, Cianci E, Simiele F, Recchiuti A. Lipoxins and aspirin-triggered lipoxins in resolution of inflammation. Eur J Pharmacol. 2015;760:49–63.CrossRefPubMed
78.
Nascimento-Silva V, Arruda MA, Barja-Fidalgo C, Fierro IM. Aspirin-triggered lipoxin A4 blocks reactive oxygen species generation in endothelial cells: a novel antioxidative mechanism. Thromb Haemost. 2007;97(1):88–98.PubMed
79.
Ho KJ, Spite M, Owens CD, Lancero H, Kroemer AH, Pande R, et al. Aspirin-triggered lipoxin and resolvin E1 modulate vascular smooth muscle phenotype and correlate with peripheral atherosclerosis. Am J Pathol. 2010;177(4):2116–23.CrossRefPubMedPubMedCentral
80.
Vital SA, Becker F, Holloway PM, Russell J, Perretti M, Granger DN, et al. Formyl-peptide receptor 2/3/Lipoxin a4 receptor regulates neutrophil-platelet aggregation and attenuates cerebral inflammation: impact for therapy in cardiovascular disease. Circulation. 2016;133(22):2169–79.CrossRefPubMed
81.
Gil-Villa AM, Norling LV, Serhan CN, Cordero D, Rojas M, Cadavid A. Aspirin triggered-lipoxin A4 reduces the adhesion of human polymorphonuclear neutrophils to endothelial cells initiated by preeclamptic plasma. Prostaglandins Leukot Essent Fat Acids. 2012;87(4–5):127–34.CrossRef
82.
Ed Rainger G, Chimen M, Harrison MJ, Yates CM, Harrison P, Watson SP, et al. The role of platelets in the recruitment of leukocytes during vascular disease. Platelets. 2015;26(6):507–20.CrossRefPubMedPubMedCentral
83.
Elajami TK, Colas RA, Dalli J, Chiang N, Serhan CN, Welty FK. Specialized proresolving lipid mediators in patients with coronary artery disease and their potential for clot remodeling. FASEB J : Off Publ Fed Am Soc Exp Biol. 2016.
84.
Dona M, Fredman G, Schwab JM, Chiang N, Arita M, Goodarzi A, et al. Resolvin E1, an EPA-derived mediator in whole blood, selectively counterregulates leukocytes and platelets. Blood. 2008;112(3):848–55.CrossRefPubMedPubMedCentral
85.
Gong Y, Lin M, Piao L, Li X, Yang F, Zhang J, et al. Aspirin enhances protective effect of fish oil against thrombosis and injury-induced vascular remodelling. Br J Pharmacol. 2015;172(23):5647–60.CrossRefPubMed
86.
Mahajan-Thakur S, Bohm A, Jedlitschky G, Schror K, Rauch BH. Sphingosine-1-phosphate and its receptors: a mutual link between blood coagulation and inflammation. Mediat Inflamm. 2015;2015:831059.CrossRef
87.
Vito CD, Hadi LA, Navone SE, Marfia G, Campanella R, Mancuso ME, et al. Platelet-derived sphingosine-1-phosphate and inflammation: from basic mechanisms to clinical implications. Platelets. 2016;27(5):393–401.CrossRefPubMed
88.
Pietri P, Vlachopoulos C, Terentes-Printzios D, Xaplanteris P, Aznaouridis K, Petrocheilou K, et al. Beneficial effects of low-dose aspirin on aortic stiffness in hypertensive patients. Vasc Med. 2014;19(6):452–7.CrossRefPubMed
89.
Soloviev MA, Kulakova NV, Semiglazova TA, Borodulina EV, Udut VV. Correction of endothelial dysfunction in patients with arterial hypertension. Bull Exp Biol Med. 2011;151(2):183–5.CrossRefPubMed
90.
Magen E, Viskoper JR, Mishal J, Priluk R, London D, Yosefy C. Effects of low-dose aspirin on blood pressure and endothelial function of treated hypertensive hypercholesterolaemic subjects. J Hum Hypertens. 2005;19(9):667–73.CrossRefPubMed
91.
Hermida RC, Ayala DE, Calvo C, Lopez JE. Aspirin administered at bedtime, but not on awakening, has an effect on ambulatory blood pressure in hypertensive patients. J Am Coll Cardiol. 2005;46(6):975–83.CrossRefPubMed
92.
Hermida RC, Ayala DE, Mojon A, Fernandez JR. Ambulatory blood pressure control with bedtime aspirin administration in subjects with prehypertension. Am J Hypertens. 2009;22(8):896–903.CrossRefPubMed
93.
Ayala DE, Hermida RC. Sex differences in the administration-time-dependent effects of low-dose aspirin on ambulatory blood pressure in hypertensive subjects. Chronobiol Int. 2010;27(2):345–62.CrossRefPubMed
94.
Hermida RC, Ayala DE, Calvo C, Lopez JE, Mojon A, Rodriguez M, et al. Differing administration time-dependent effects of aspirin on blood pressure in dipper and non-dipper hypertensives. Hypertension. 2005;46(4):1060–8.CrossRefPubMed
95.
Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Böhm M, et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension. Eur Heart J. 2013;34(28):2159–219.CrossRefPubMed
96.
Bibbins-Domingo K. Aspirin use for the primary prevention of cardiovascular disease and colorectal cancer: U.S. Preventive Services Task Force Recommendation StatementAspirin Use for the Primary Prevention of CVD and CRC. Ann Intern Med. 2016;164(12):836–45.CrossRefPubMed
97.
98.
Santilli F, Pignatelli P, Violi F, Davì G. Aspirin for primary prevention in diabetes mellitus: from the calculation of cardiovascular risk and risk/benefit profile to personalised treatment. Thromb Haemost. 2015;114(11):876–82.CrossRefPubMed
99.
Kunutsor SK, Seidu S, Khunti K. Aspirin for primary prevention of cardiovascular and all-cause mortality events in diabetes: updated meta-analysis of randomized controlled trials. Diabetic Med: J British Diabetic Assoc. 2016.
100.
Bartolucci AA, Howard G. Meta-analysis of data from the six primary prevention trials of cardiovascular events using aspirin. Am J Cardiol. 2006;98(6):746–50.CrossRefPubMed
101.
Baigent C, Blackwell L, Collins R, Emberson J, Godwin J, Peto R, et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet (London, England). 2009;373(9678):1849–60.CrossRef
102.
Bartolucci AA, Tendera M, Howard G. Meta-analysis of multiple primary prevention trials of cardiovascular events using aspirin. Am J Cardiol. 2011;107(12):1796–801.CrossRefPubMed
103.
Raju N, Sobieraj-Teague M, Hirsh J, O’Donnell M, Eikelboom J. Effect of aspirin on mortality in the primary prevention of cardiovascular disease. Am J Med. 2011;124(7):621–9.CrossRefPubMed
104.
Raju N, Sobieraj-Teague M, Bosch J, Eikelboom JW. Updated meta-analysis of aspirin in primary prevention of cardiovascular disease. Am J Med. 2016;129(5):e35–6.CrossRefPubMed
105.
• Guirguis-Blake JM, Evans CV, Senger CA, O’Connor EA, Whitlock EP. Aspirin for the Primary Prevention of Cardiovascular Events: A Systematic Evidence Review for the U.S. Preventive Services Task ForceAspirin for the Primary Prevention of Cardiovascular Events. Ann Intern Med. 2016;164(12):804–13. A systematic review of effectiveness of aspirin for primary prevention of cardiovascular events.CrossRefPubMed
106.
• Whitlock EP, Burda BU, Williams SB, Guirguis-Blake JM, Evans CV. Bleeding risks with aspirin use for primary prevention in adults: a systematic review for the U.S. Preventive Services Task Force Bleeding Risks With Aspirin Use. Ann Intern Med. 2016;164(12):826–35. A systematic review of safety of aspirin for primary prevention of cardiovascular events.CrossRefPubMed
107.
108.
ASPREE Investigator Group. Study design of ASPirin in Reducing Events in the Elderly (ASPREE): a randomized, controlled trial. Contemp Clin Trials. 2013;36(2):555–64.CrossRefPubMedCentral
109.
De Berardis G, Sacco M, Evangelista V, Filippi A, Giorda CB, Tognoni G, et al. Aspirin and Simvastatin Combination for Cardiovascular Events Prevention Trial in Diabetes (ACCEPT-D): design of a randomized study of the efficacy of low-dose aspirin in the prevention of cardiovascular events in subjects with diabetes mellitus treated with statins. Trials. 2007;8:21.CrossRefPubMedPubMedCentral
110.
Aung T, Haynes R, Barton J, Cox J, Murawska A, Murphy K, et al. Cost-effective recruitment methods for a large randomised trial in people with diabetes: A Study of Cardiovascular Events iN Diabetes (ASCEND). Trials. 2016;17(1):286.CrossRefPubMedPubMedCentral
111.
112.
Le Quellec S, Bordet JC, Negrier C, Dargaud Y. Comparison of current platelet functional tests for the assessment of aspirin and clopidogrel response. A review of the literature. Thrombosis Haemostasis. 2016(2016-07-21 00:00:00).
113.
Krasopoulos G, Brister SJ, Beattie WS, Buchanan MR. Aspirin “resistance” and risk of cardiovascular morbidity: systematic review and meta-analysis. BMJ. 2008;336(7637):195–8.CrossRefPubMedPubMedCentral
114.
Snoep JD, Hovens MM, Eikenboom JC, van der Bom JG, Huisman MV. Association of laboratory-defined aspirin resistance with a higher risk of recurrent cardiovascular events: a systematic review and meta-analysis. Arch Intern Med. 2007;167(15):1593–9.CrossRefPubMed
115.
Pettersen AA, Arnesen H, Seljeflot I. A brief review on high on-aspirin residual platelet reactivity. Vasc Pharmacol. 2015;67–69:6–9.CrossRef
116.
Nagatsuka K, Miyata S, Kada A, Kawamura A, Nakagawara J, Furui E, et al. Cardiovascular events occur independently of high on-aspirin platelet reactivity and residual COX-1 activity in stable cardiovascular patients. Thrombosis Haemostasis. 2016;116(2).
117.
Brun C, Daali Y, Combescure C, Zufferey A, Michelson AD, Fontana P, et al. Aspirin response: Differences in serum thromboxane B2 levels between clinical studies. Platelets. 2016;27(3):196–202.CrossRefPubMed
118.
Homorodi N, Kovacs EG, Lee S, Katona E, Shemirani AH, Haramura G, et al. The lack of aspirin resistance in patients with coronary artery disease. J Transl Med. 2016;14:74.CrossRefPubMedPubMedCentral
119.
Freynhofer MK, Gruber SC, Grove EL, Weiss TW, Wojta J, Huber K. Antiplatelet drugs in patients with enhanced platelet turnover: biomarkers versus platelet function testing. Thromb Haemost. 2015;114(9):459–68.CrossRefPubMed
120.
Kakouros N, Nazarian SM, Stadler PB, Kickler TS, Rade JJ. Risk factors for nonplatelet thromboxane generation after coronary artery bypass graft surgery. J Am Heart Assoc. 2016;5(3), e002615.CrossRefPubMedPubMedCentral
121.
Christensen KH, Grove EL, Wurtz M, Kristensen SD, Hvas AM. Reduced antiplatelet effect of aspirin during 24 hours in patients with coronary artery disease and type 2 diabetes. Platelets. 2015;26(3):230–5.CrossRefPubMed
122.
Henry P, Vermillet A, Boval B, Guyetand C, Petroni T, Dillinger JG, et al. 24-hour time-dependent aspirin efficacy in patients with stable coronary artery disease. Thromb Haemost. 2011;105(2):336–44.CrossRefPubMed
123.
Larsen SB, Grove EL, Neergaard-Petersen S, Wurtz M, Hvas AM, Kristensen SD. Determinants of reduced antiplatelet effect of aspirin in patients with stable coronary artery disease. PLoS ONE. 2015;10(5), e0126767.CrossRefPubMedPubMedCentral
124.
• Doroszko A, Szahidewicz-Krupska E, Janus A, Jakubowski M, Turek A, Ilnicka P, et al. Endothelial dysfunction in young healthy men is associated with aspirin resistance. Vasc Pharmacol. 2015;67–69:30–7. A study showing association between endothelial function and effectivenes of aspirin therapy.CrossRef
125.
• Larsen SB, Grove EL, Wurtz M, Neergaard-Petersen S, Hvas AM, Kristensen SD. The influence of low-grade inflammation on platelets in patients with stable coronary artery disease. Thromb Haemost. 2015;114(3):519–29. A study showing impact of vascular inflammation on platelets aggregation.CrossRefPubMed
126.
Stratz C, Nuehrenberg T, Amann M, Cederqvist M, Kleiner P, Valina CM, et al. Impact of reticulated platelets on antiplatelet response to thienopyridines is independent of platelet turnover. Thrombosis Haemostasis. 2016(2016-08-04 00:00:00).
Metadata
Title
Effects of Aspirin on Endothelial Function and Hypertension
Authors
Mikhail S. Dzeshka
Alena Shantsila
Gregory Y. H. Lip
Publication date
01-11-2016
Publisher
Springer US
Published in
Current Hypertension Reports / Issue 11/2016
Print ISSN: 1522-6417
Electronic ISSN: 1534-3111
DOI
https://doi.org/10.1007/s11906-016-0688-8

Other articles of this Issue 11/2016

Current Hypertension Reports 11/2016 Go to the issue

Resistant Hypertension (E Pimenta, Section Editor)

Should All Patients with Resistant Hypertension Receive Spironolactone?

Antihypertensive Agents: Mechanisms of Drug Action (M Ernst, Section Editor)

Hypertension in Athletes and Active Populations

Blood Pressure Monitoring and Management (J Cockcroft, Section Editor)

Isolated Systolic Hypertension in Young and Middle-Aged Adults

Hypertension and Obesity (E Reisin, Section Editor)

Endoluminal Treatments for Obesity and Related Hypertension: Updates, Review, and Clinical Perspective

Hypertension and Obesity (E Reisin, Section Editor)

A Clinical Perspective: Contribution of Dysfunctional Perivascular Adipose Tissue (PVAT) to Cardiovascular Risk

Antihypertensive Agents: Mechanisms of Drug Action (M Ernst, Section Editor)

White Coat Hypertension: to Treat or Not to Treat?
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits